In advanced PCa and AR-inhibited phenotypes, the activity of DRP1 and MYC is increased, resulting in a glycolytic shift and resistance phenotypes in AR blockade therapy-resistant PCa [129]. The gene discussed is DNM1L; the disease is posterior cortical atrophy.